A Positron Emission Tomography (PET) scan is an imaging test that uses radioactive substance to measure important body functions. These scans can show how well organs and tissues are working, which are useful for disease detection before it is evident on other imaging tests.
Amyloid Positron Emission Tomography (PET) imaging represents a major advancement in the assessment of those with cognitive impairment. The scan visualizes the density of beta amyloid neuritic plaque in the brain, which is the primary cause of Alzheimer’s disease.
Amyloid PET scan is made possible by the development of Vizamyl (Flutemetamol F 18). Vizamyl is a radioactive diagnostic agent for PET imaging of the brain. It assesses the neuritic plaque density in adult patients with cognitive impairment, and helps in the evaluation of Alzheimer’s disease or other cognitive decline.
Vizamyl is the only PET imaging tracer for detecting amyloid approved by the FDA. It provides visual interpretation with color mapping of affected brain tissues, as compared to traditional tracers which were only available in black and white.
For more enquiries or to make an appointment, call (65) 6705 2777.
Reference:
GE Healthcare
1. http://www3.gehealthcare.com/en/products/categories/nuclear_imaging_agents/vizamyl
2. SNMMI Procedure Standard-EANM Practice Guideline for Amyloid PET Imaging of the Brain